Inventiva Moves Up In NASH, Hitting Multiple Phase IIb Endpoints

One month after competitor Genfit SA crashed with a Phase III failure in NASH, Inventiva Pharma is moving toward the front of the pack in non-alcoholic steatohepatitis with Phase IIb data showing that its lanifibranor can improve hepatocellular inflammation and ballooning, reduce fibrosis and resolve NASH. The Daix, France-based firm noted it is the first company to meet both regulatory endpoints for NASH approval – resolution and fibrosis reduction – in the same clinical trial.

Lanifibranor, a pan-PPAR agonist, met its primary endpoint of reducing the Steatosis Activity Fibrosis (SAF) score from baseline at six months compared to placebo in top-line data reported on 16...